Moderna seeks regulatory approval for its COVID-19 vaccine

Mumbai-based pharmaceutical firm Cipla, on behalf of the U.S. pharma major, has requested for import and marketing authorisation of these jabs

India’s drug regulator may soon grant restricted emergency use authorisation for Moderna’s COVID-19 vaccine, official sources said on June 29.

Moderna has also informed that the U.S. Government has agreed to donate a certain number of doses of the Moderna COVID-19 vaccine through COVAX to the Government of India for use and has sought approval from the Central Drugs Standard Control Organisation (CDSCO) for these vaccines.

Mumbai-based pharmaceutical firm Cipla, on behalf of the U.S. pharma major, has requested for import and marketing authorisation of these jabs.

According to the sources, an approval is likely to come anytime as the CDSCO is in favour of doing so.

Cipla filed an application on Monday seeking permission for import of Moderna COVID-19 vaccine referring to DCGI notices dated April 15 and June 1 stating that if the vaccine is approved by the USFDA for EUA, the vaccine can be granted marketing authorisation without bridging trial and assessment of safety data of first 100 beneficiaries of vaccines shall be submitted before rolling out in immunisation programme.

Crime Today News | Business


Source

CrimeTodayNews

Crime Today News is an online news website that conveys the data you have to know. We will likely transform information into data and data into understanding.

Related Posts